What is Delve Bio?
Delve Bio operates at the intersection of advanced genomics and clinical diagnostics. By leveraging high-throughput metagenomic sequencing technologies, the company provides critical insights into complex biological data, enabling more precise identification of pathogens and disease markers. As a key player in the medtech ecosystem, Delve Bio bridges the gap between raw genomic data and actionable clinical intelligence. Its market position is bolstered by a commitment to enterprise-level scalability, ensuring that its diagnostic tools can be integrated into diverse healthcare environments, from research laboratories to large-scale clinical facilities.
How much funding has Delve Bio raised?
Delve Bio has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Section 32, GV, and Xontogeny Venture Fund II
Key Investors in Delve Bio
Section 32
A venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and visionary entrepreneurs at the forefront of technological advancement.
GV
A global venture capital firm that invests across multiple stages and sectors, with a strong emphasis on life sciences, enterprise solutions, and frontier technology innovations.
Xontogeny Venture Fund II
A specialized venture fund focused on supporting early-to-mid-stage life science companies through strategic capital and operational expertise.
What's next for Delve Bio?
Following this major enterprise-level funding, Delve Bio is expected to prioritize the commercialization of its core sequencing infrastructure. The strategic allocation of capital will likely focus on enhancing operational efficiency, expanding the company's R&D capabilities, and strengthening its competitive advantage in the life sciences sector. By deepening its engagement with institutional partners and scaling its diagnostic throughput, Delve Bio aims to solidify its status as a foundational provider of metagenomic solutions. The firm's trajectory suggests a transition toward broader market penetration, with a focus on delivering high-fidelity data to support precision medicine initiatives globally.
See full Delve Bio company page
